Liv Labs

Liv Labs targeted 78 million American women experiencing pelvic floor weakness, positioning Pippa as a fitness device for an underserved market where existing solutions felt clinical or ineffective. ​​‌‌‌‌‌‌‌​‌‌​​‌​​​​​​‌‌​‌‌‌​​​‌‌The founders assumed women would embrace a consumer wellness approach rather than medical framing, betting that positioning pelvic floor training alongside mainstream fitness—not gynecology—would drive adoption. Their Y Combinator backing and October 2025 launch suggest early validation of this positioning resonated with investors who recognized the massive addressable market and daily anxiety affecting 31 million women. The company's emphasis on "fitness made easy" and "lifelong" strength indicates they believed accessibility and habit-formation would differentiate Pippa from clinical alternatives. However, detailed customer acquisition data remains limited in available sources. What's clear is that Liv Labs identified a genuine pain point with substantial prevalence, then reframed it as a wellness category problem rather than a medical one—a strategic choice that likely influenced both their product design and go-to-market approach, though specific early customer feedback or retention metrics aren't documented here.